抗VEGF药物安全性概览:意大利自发报告系统分析
本研究利用意大利自发报告系统,分析抗VEGF药物在肿瘤与眼科适应症中的疑似不良反应报告,按使用途径分层描述频率并计算报告比值比。共2472份报告中,全身用药2173份(87.9%),玻璃体腔注射299份(12.1%)。玻璃体腔注射的严重ADR报告频率高于肿瘤患者全身用药(58.9% vs 34.1%,p<0.001),且与缺血性心脏病及血栓栓塞、脑血管事件呈比例失衡关联。
要点
- 玻璃体腔注射抗VEGF药物严重ADR报告频率高于肿瘤全身用药(58.9% vs 34.1%)。
- 玻璃体腔注射与缺血性心脏病及血栓栓塞、脑血管事件呈比例失衡关联。
- 肿瘤患者全身用药的严重ADR多为已知且临床相关(如胃肠和血管疾病)。
核心结论
- 玻璃体腔注射抗VEGF药物也可能发生严重ADR和全身毒性。
- 所有抗VEGF药物治疗期间应考虑密切监测心脑血管不良事件。
研究设计与样本
- 基于意大利自发报告系统的描述性频率分析,按使用适应症分层。
- 共纳入2472份抗VEGF药物相关疑似ADR报告。
主要发现
- 全身用药报告2173份(87.9%),玻璃体腔注射报告299份(12.1%)。
- 玻璃体腔注射严重ADR报告频率为58.9%,肿瘤全身用药为34.1%(p<0.001)。
- 玻璃体腔注射与缺血性心脏病及血栓栓塞、脑血管事件呈比例失衡关联。
- 肿瘤患者全身用药的严重ADR多为已知且临床相关(如胃肠和血管疾病)。
关键数值与推荐
- 以报告比值比(PRR)及95%CI在MedDRA标准化查询(SMQ)层面衡量比例失衡。
临床怎么用
- 使用抗VEGF药物(包括玻璃体腔注射)时应关注严重ADR和全身毒性。
- 治疗期间考虑密切监测心脑血管不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Anti-vascular endothelial growth factor (anti-VEGF) drugs are widely used for the treatment of several cancers and retinal diseases. The systemic use of anti-VEGF drugs has been associated with an increased risk of serious adverse reactions. Whether this risk is also related to intravitreal administration of anti-VEGF drugs is unclear. OBJECTIVE: The aim of this study was to provide an overview of the safety of anti-VEGF drugs in oncology and ophthalmology settings using the Italian Spontaneous Reporting System (SRS). METHODS: We selected all suspected adverse drug reaction (ADR) reports attributed to anti-VEGF drugs and conducted descriptive frequency analyses stratified by indication of use. As a measure of disproportionality, we calculated the proportional reporting ratio with 95% confidence intervals at the level of standardized Medical Dictionary for Regulatory Activities (MedDRA®) queries (SMQs). RESULTS: Of a total of 2472 anti-VEGF drug-related reports, 2173 (87.9%) and 299 (12.1%) were attributed to systemic and intravitreal use of these drugs, respectively. The frequency of serious ADRs reported was higher for intravitreal administration of anti-VEGF drugs than for systemic use in patients with cancer (58.9 vs. 34.1%) (p < 0.001) and were disproportionally associated with ischemic heart disease and thromboembolic and cerebrovascular events. Most serious ADRs related to anti-VEGF drugs in patients with cancer are known and clinically relevant (e.g., gastrointestinal and vascular disorders). CONCLUSIONS: This study documented that serious ADRs and systemic toxicity may occur not only with systemic use of anti-VEGF drugs in patients with cancer but also with intravitreal administration. Close monitoring of cardio/cerebrovascular adverse events should be considered during treatment with all anti-VEGF drugs.
引用
- Cutroneo PM, Giardina C, Ientile V, et al. Overview of the Safety of Anti-VEGF Drugs: Analysis of the Italian Spontaneous Reporting System. Drug Saf. 2017. PMID: 28585152. doi:10.1007/s40264-017-0553-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。